(Q38177842)

30 August 2017

title

We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it? (English)

1 reference

30 August 2017

1

1 reference

30 August 2017

Niedja M Arruda

2

1 reference

30 August 2017

Walter O Arruda

3

1 reference

30 August 2017

Joseph B B Brooks

4

1 reference

30 August 2017

Eber C Correa

5

1 reference

30 August 2017

Alfredo Damasceno

6

1 reference

30 August 2017

Carlos A Damasceno

7

1 reference

30 August 2017

Maria L B Ferreira

8

1 reference

30 August 2017

Maria C B Giacomo

9

1 reference

30 August 2017

Sidney Gomes

10

1 reference

30 August 2017

Marcus V M Gonçalves

11

1 reference

30 August 2017

Anderson K Grzesiuk

12

1 reference

30 August 2017

Damacio R Kaimen-Maciel

13

1 reference

30 August 2017

Josiane Lopes

14

1 reference

30 August 2017

Suzana C N Machado

15

1 reference

30 August 2017

Celso L S Oliveira

16

1 reference

30 August 2017

Carla R A V Stella

17

1 reference

30 August 2017

publication date

13 January 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

30 August 2017

published in

1 reference

30 August 2017

volume

14

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

127-130

1 reference

Update on therapeutic options for multiple sclerosis

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Best practice in the use of natalizumab in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Natalizumab adverse events are rare in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.874947

10.1586/14737175.2014.874947

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference